ECF trades at 31% discount to $1.02 fair value with 10.7% yield, 96.3% occupancy vs 94% peers, facing external management transition risks
View notePre-commercial cardiac device company with negative $(0.24) fair value. 77% revenue CAGR offset by permanent -178% EBITDA margins. 75% probability of value destruction versus 25% strategic acquisition hope.
View noteSELL rating with fair value $18.62 vs current $30.24. Healthcare distribution leader faces margin compression and direct distribution threats.
View noteSELL rating with fair value $4.71 vs current $7.42. Office REIT facing structural headwinds from hybrid working, 64% downside risk.
View noteHOLD rating with $2.39 fair value vs $2.80 current price. Exceptional 98.6% occupancy offset by development execution risks and overvaluation concerns.
View noteREDUCE rating with $5.50 target vs $9.06 current. Fair value $5.07 implies 44% downside. 71% ROIC, debt-free balance sheet offset by Microsoft dependency and margin compression.
View noteIndustrial cooling manufacturer trading 58% above $2.65 fair value with deteriorating competitive moat, value-destructive ROIC of 7.5% vs 10.5% WACC, and technology disruption risks.
View noteInfrastructure services leader trading at $6.89 vs $9.78 fair value following successful transformation. EBITDA margins at 10-year highs, 42% upside potential.
View noteInfrastructure monopoly trading at $4.77 vs $3.11 fair value. 6.0x leverage, 2031 regulatory renewal risk, 91% DCF downside. Quality score 5.1/10.
View noteCyclopharm trades at $0.99 vs $1.18 fair value with 85% global market share in lung imaging, 29% revenue CAGR projected through US expansion
View noteHold rating with $7.84 fair value vs $7.37 current price. Strong execution capabilities offset by inevitable margin compression as housing shortage normalises.
View noteProfitable biotech rarity with 90% EPP monopoly and transformational vitiligo opportunity. Fair value $19.94 vs current $10.89 implies 83% upside. Quality score 7.9/10.
View note